The latest advances in treating common eye disorders give hope to patients. From innovative gene therapies to nanomedicine, new treatments are becoming a reality for those suffering from a variety of eye conditions. This article briefly covers useful information about improving your visual health.

Cutting-edge approaches improve patient outcomes and offer new possibilities for vision restoration and maintenance. Gene therapies such as Luxturna™, 3-D printing of retinal cells, nanomedicine, FDA-approved implants such as Ozurdex®, are revolutionary examples that support performance and efficiency. in eye medicine.

To discover how these treatments can benefit you or your loved ones, continue reading, also accessing the bibliographic sources.

Overview of eye disorders

In the United States, the primary causes of blindness and low vision are age-related eye diseases, including age-related macular degeneration (AMD), cataract, diabetic retinopathy (DR), and glaucoma, along with common disorders like amblyopia (a lazy eye) and strabismus (squint). Refractive errors such as myopia (short-sightedness), hyperopia (long-sightedness), astigmatism, and presbyopia are the most frequent eye issues, often correctable by glasses, contact lenses, or surgery. AMD affects central vision and has both wet and dry forms, with the latter being more common. Cataracts, leading to vision loss and treatable by surgery, are prevalent, particularly in older adults. DR, resulting from diabetes, progresses through several stages and is a major cause of blindness in adults. Glaucoma, which damages the optic nerve, often goes unnoticed until advanced stages. Amblyopia, commonly known as lazy eye, and strabismus, an eye alignment disorder, are significant causes of vision impairment, particularly in children.¹

Overview of eye anatomical barriers

Administering medications to ocular tissues can be done through various methods such as topical, subconjunctival, suprachoroidal, intracameral, intravitreal, retrobulbar, sub-tenon, posterior juxta-scleral, subretinal, and systemic delivery. The most common routes are topical, systemic, periocular, and intraocular, used for many ocular conditions seen in clinical practice. Topical application is the simplest, including solutions, suspensions, ointments, gels, and emulsions. However, only about 5% of the dose reaches the internal eye structures due to barriers like the tear film, cornea, vitreous, blood-aqueous barrier, and blood-retina barrier. These barriers protect against harmful external molecules but also limit drug bioavailability. The blood-retina barrier restricts drug absorption from systemic circulation to the posterior eye, while the other barriers prevent the absorption of externally applied drugs into the anterior and posterior segments. Effective ocular drug delivery faces challenges due to these anatomical barriers, with topical and systemic applications struggling with barrier penetration and rapid clearance, especially for the posterior eye segment. Alternative routes, such as injections, face issues like patient compliance, frequent injections, and injection-related side effects.²

Advances in gene therapy

Gene therapies for ocular disorders have seen a significant rise in development due to advancements in viral vector technology and a better understanding of the genetic basis of these conditions. This progress culminated in 2017 with the FDA approval of Luxturna™, the first gene therapy for the eyes. Luxturna™ uses adeno-associated viruses (AAVs) to deliver therapeutic genes to retinal cells, providing new treatment options for inherited retinal diseases and other ocular disorders.³

AMD is the leading cause of irreversible central vision loss in individuals over 65, affecting over 1.8 million Americans. Gene therapies targeting this condition aim to slow or halt disease progression by delivering genes that can protect or restore retinal function.³

Similarly, DR, a common complication of diabetes mellitus, leads to preventable vision loss. Gene therapy research is exploring ways to prevent or reverse the vascular damage caused by high blood sugar levels.³

Glaucoma, a neurodegenerative disease that damages the optic nerve, is the leading cause of irreversible blindness worldwide. Gene therapies are being developed to protect retinal ganglion cells and their axons from degeneration. Corneal diseases, which are the fourth leading cause of blindness globally, are also being targeted by gene therapies to improve corneal health and vision.³

Development of non-viral DNA delivery systems

Research into non-viral DNA delivery systems, such as solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), is advancing. These modified liposomes are designed for better gene and drug delivery than traditional methods.³

Polymer and peptide nanoparticles (PNPs) are being investigated as alternatives to lipid-based nanoparticles for DNA delivery. Dendrimers, which are branched organic polymers, and nanoemulsions, stable mixtures of immiscible liquids, offer new avenues for gene delivery.³

Lipid-based nanoparticles, including nanomicelles, liposomes, and niosomes, are being used for ocular drug delivery due to their ability to encapsulate and protect therapeutic agents.³

Innovative carrier technologies

Advancements in ocular vector technology have led to improved carrier systems that maintain therapeutic drug concentrations at target sites, overcome ocular barriers, reduce administration frequency, and enhance drug bioavailability. These advancements are essential for effective gene therapy, as the unique anatomy and natural barriers of the eye present significant challenges.³

Nanomedicine in ophthalmology focuses on using nanoparticles for diagnosis, monitoring, and treatment. These nanoparticles serve as ideal ocular drug carriers due to their customisable properties like mucoadhesion, biocompatibility, and biodegradability, enhancing drug permeation. Nanobiotechnology offers personalised treatments by considering disease progression and treatment responses, enabling adjustments in pharmacogenetics and pharmacoproteomics for tailored therapies.⁴

Numerous ocular diseases can be treated with various FDA-approved implants. Notable examples include Iluvien^®, Ozurdex^®, and Dexycu^®, which are biodegradable and bioresorbable. Ozurdex^®, made from a copolymer of lactic and glycolic acids with micronised dexamethasone, is mainly used to treat uveitis. Recent studies have demonstrated Ozurdex^®'s efficacy and safety in treating different forms of uveitis, with minimal side effects reported. Additionally, research suggests that Ozurdex^® could potentially replace systemic corticosteroid therapy, mitigating the unpleasant side effects associated with high-dose corticosteroids.²

Advances in intraocular administration routes

Intraocular administration routes and systemic delivery methods are also evolving. For the anterior segment of the eye, subconjunctival, intrastromal, and intracameral administrations are used. For the posterior segment, intravitreal, subretinal, and suprachoroidal administrations are being explored to minimise drug loss and improve delivery to the retina and other deeper structures.³

A groundbreaking development in ophthalmology is the use of 3-D printing technology to create retinal cells. Lorber and colleagues demonstrated that an inkjet printer could successfully print retinal ganglion and glial cells from adult rats. These printed cells remained viable and capable of growth in culture, suggesting the potential for creating artificial retina grafts. However, extensive scientific validation is needed to confirm this technology's effectiveness in treating blindness.⁴

Challenges and future directions

Despite the challenges of ocular drug delivery, gene therapy for ocular diseases is advancing rapidly. The combined efforts of academia, industry, and regulatory agencies are continually improving the safety and efficacy of these therapies. Advances in viral and non-viral vectors, along with novel carrier systems, are expanding the scope of gene delivery and showing promising results in clinical trials. The continued development of these technologies will enhance therapeutic outcomes and provide new hope for patients with ocular disorders.³

Summary

The article provides a comprehensive overview of the primary causes of blindness and low vision in the United States, focusing on age-related eye diseases such as AMD, cataracts, DR, and glaucoma, as well as common conditions like amblyopia and strabismus. It highlights the anatomical barriers of the eye that challenge effective drug delivery, noting that only about 5% of topically applied drugs penetrate the internal eye structures due to protective barriers like the tear film, cornea, and blood-retina barrier.

Recent advancements in gene therapy and non-viral DNA delivery systems are discussed, emphasising the progress made with FDA-approved Luxturna™ for inherited retinal diseases. The development of innovative carrier technologies and nanomedicine in ophthalmology shows promise in enhancing drug permeation and personalized treatment approaches.

The article also covers the evolution of intraocular administration routes and the groundbreaking use of 3-D printing technology to create retinal cells, which could potentially lead to artificial retina grafts. Despite the challenges, ongoing research and collaboration among academia, industry, and regulatory bodies are improving the safety and efficacy of ocular therapies, offering new hope for patients with eye disorders.